TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
AMRN

Amarin Corporation PLC

Healthcare · Drug Manufacturers - General

13.30$ +0.4% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Amarin Corporation PLC (AMRN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.9% of the shares are freely tradable; institutional investors hold 23.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 23.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 37.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 91.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 21Mio.

Largest Shareholders

Institutions

Institutions AMRN
Name Stake (%) Shares Change (%) Date
Sarissa Capital Management LP 7.92 1,673,395 +0.0 06/30/2026
Acadian Asset Management LLC 3.01 636,769 +0.0 03/31/2026
Kynam Capital Management, LP 2.52 532,982 +12.8 06/30/2026
Morgan Stanley - Brokerage Accounts 1.39 293,172 -11.2 03/31/2026
Point72 Asset Management, L.P. 1.14 240,761 +559.8 03/31/2026
Waterfront Wealth Inc. 1.01 213,949 +5.2 06/30/2026
Brooklands Fund Management Limited 0.84 177,325 +1,037.0 06/30/2026
Eversept Partners, LP 0.69 145,296 -1.6 06/30/2026
Millennium Management LLC 0.55 115,808 -61.5 06/30/2026
Two Sigma Investments LLC 0.48 100,511 -6.5 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?